What is the Oncotype DX® Breast DCIS Score™?

The Oncotype DX test for patients with ductal carcinoma in situ (DCIS) is a diagnostic test developed to help patients who have been recently diagnosed with DCIS, and their doctors learn more about their specific tumor and create a better treatment plan. After a patient is diagnosed with DCIS, doctors and patients work together to plan the best course of treatment. Along with other pieces of information, the Oncotype DX test can help guide treatment decision-making in women with DCIS once the tumor is removed by surgery.

The test can also help doctors determine the likelihood of DCIS returning or the tumor returning as invasive breast cancer in the same location, also known as local recurrence.

The Oncotype DX test works by examining a sample of the tumor tissue that has already been removed during the original surgery. The test measures a group of cancer genes in the tissue sample to see how active they are (also known as how they are expressed). The result of the test is reported as a number between 0 and 100, known as the DCIS Score results, and is plotted in two separate graphs. One graph represents the chances of any tumor coming back in the same breast (either a DCIS or invasive breast cancer). A lower DCIS Score result means there is a lower chance that this will occur, and a higher score means that there is a higher chance that this will occur. The other graph represents the chances of the tumor coming back in the same breast as an invasive breast cancer. A lower score means there is a lower chance that this will occur, and a higher score means that there is a higher chance that this will occur.

The Breast DCIS Score results help guide personalized treatment decisions. Because everyone’s body and tumor are unique, obtaining a DCIS Score result helps make treatment decisions tailored to you.

The Breast DCIS Score provides information in addition to traditional measurements (such as margin width, tumor size and tumor grade) that doctors have traditionally used to estimate how likely a patient’s cancer is to return, and to help them make treatment decisions.

In addition to DCIS, Genomic Health (the company that developed the Oncotype DX test) offers tests for invasive breast cancer, colon cancer and prostate cancer. To date, the combined Oncotype DX tests have been ordered by over 19,000 doctors in over 90 countries, for more than 700,000 patients.

Steps of the Oncotype DX test

Next: How Was the Test Developed?